Divi's Lab Q2 FY27: Profit +64% to ₹1,127 Cr, EBITDA Doubles

💊 Pharma API leader DIVISLAB just reported a very strong Q2 FY27 (results on 7 Nov 2026). Here is a quick, data-first breakdown: ✅ Revenue from operations: ₹3,676 Cr vs ₹2,715 Cr a year ago (+35% YoY) ✅ Net profit: ₹1,127 Cr vs ₹689 Cr (+64% YoY) ✅ EBITDA (ex other income): ~₹1,566 Cr, almost double YoY; margin ~42.6% ✅ Sequential growth too: revenue +19% and profit +25% vs Q1 FY27 ✅ What to track next: custom synthesis (CDMO) order flow, new product launches, capacity ramp-up, and whether this margin level is sustainable ✅ Risk check: pharma stocks with premium valuations can react sharply to any slowdown in growth, currency moves or US regulatory news Big question for you 👇 Is this the start of a new multi-year CDMO growth cycle for Indian pharma, or is the strong quarter already priced in? Share your view in the comments! 📲 For daily market notes, search "Neha Gupta SEBI RA" on Telegram and join the FREE channel. Neha Gupta | SEBI Registered Research Analyst | Reg. No. INH000016542 ⚠️ Disclaimer: This content is for educational purposes only and is not investment advice or a buy/sell recommendation. Investments in the securities market are subject to market risks. Read all related documents carefully before investing.